




for Hemoglobinopathies

Suthat Fucharoen M.D.


Thalassemia Research Center
Institute of Molecular Biosciences
Mahidol University, Thailand
(suthat.fuc@mahidol.ac.th)



THALASSEMIA CENTER



THALASSEMIA CENTER



Outline of my talk:

- 1) TIF recommendation
- 2) Thalassemia Center, Torino, Italy (Antonio Piga)
- 3) Thalassemia prevention, Guagxi, China
“Nanning Declaration”
- 4) SEARO/WHO

Aims of Management

- Long Survival
- Good Quality of Life

Survival of patients

- Optimum treatment required for survival and quality of life.
- No treatment means early death
- Less treatment means poor quality of life and early death

Factors affecting survival

- The treatment protocol
- Adherence to it
- Family support
- Psychosocial support
- Quality of follow-up
- Early recognition and intervention of complications

Quality of life

- **Good clinical condition**
- **Psychosocial support**
- **Endocrinological monitoring of growth, puberty, hypogonadism, amenorrhoea, reproduction**
- **Complications e.g. diabetes, heart**
- **Bone pains**
- **Employment, marriage**


Patient care

- Voluntary blood donation
- Safe blood
- Provision of essential drugs, chelating agents
- Free medical treatment
- Expert Reference Centers. Quality of care.
- Psychosocial support
- National registers

Patients must also cope with:

- The disease, its complications and chronicity
- Demanding treatment, especially chelation
- Family: supportive but may increase stress
- Caregivers (doctors/nurses) – overprotective, or figures of authority
- Society: peer relationships, stigmatisation, education, career, marriage

Survival of thalassemia patients in Cyprus by birth cohort



Comprehensive care

- Treating the whole person and the family, through continuous supervision of all the medical and psychosocial aspects...
- Every facet of the person – physical, emotional, psychological, educational, financial and vocational factors are addressed
- www.hemophilia.org

Comprehensive care?

- In a European survey (Enerca) – *20.5% of thalassaemia patients wait for more than 2 hours for the blood transfusion.*
- *61.7% are transfused in the mornings – to suit the hospital without considering the educational (50% attend school or university) or employment (13% work full time) commitments of the patients*

Patient needs – rarely satisfied

- 271 hours per month are spent on blood transfusions, chelation, other medical appointments, travel time, phoning'

Compagno LM et al Ann NY Acad Sci, 2005

- Transfusion times to suite education and work
- Shortening waiting time
- Increasing communication time

Time

- **Average time doctor spends with a patient in the US: 18.7 minutes**
- **Average time doctor spends with a patient in Germany: 15 minutes**
- **What about patients with chronic disorders?**
- ***What about Thailand? Medical Center vs Provincial hospital***

The need for expert centres

- A centre where the quality of comprehensive, patient centred, care is assured
- The capacity to provide expert diagnosis or confirmation of diagnosis, including genetic tests and genetic counselling
- Laboratory as well as clinical capacity
- Training and education of stakeholders and service providers

Expert Centre

Adapted from the EU Task Force Criteria

- A centre where the quality of comprehensive care is assured
- Where there is the capacity to provide expert diagnosis
- Well qualified staff with experience
- Supporting- self management
- Networking with secondary centres but also with other expert centres

Expert thalassaemia centre

The capacity to provide expert case management:

- Good practice guidelines and protocols
- Expert advice & information to patients
- Multidisciplinary team- coordinated
- Psychosocial support
- Staff/patient ratio

Patient-friendly services

- **Staff willing to spend time and to listen**
- **Privacy and confidentiality**
- **Discuss sexuality, contraception, puberty, diet, risky behaviour, school problems, etc.**
- **Convenient appointment times – consider school and work**
- **Patients feel welcome and safe**

Clinical information systems

- Using technology to organise data
- Monitoring patient health status
- Electronic patient records
- Identifying patient sub-groups for pro-active interventions
- Rights of patients to the contents of their records
- Electronic patient registries
- Networking between centres nationally and internationally

Decision support in thalassaemia centres

- Evidence-based guidelines (updated)
- National standards for optimal care
- Regular training of staff in using protocols
- Sharing information with patients
- Electronic infrastructure, telemedicine, videoconferencing between doctors, etc.

Delivery system design

- Coordinating the multidisciplinary team
- Defining roles in the team
- Regular follow up of patients
- Communicating with the patient at home
- Collaboration with primary care services and supporting local physicians

Self-management support

- Patient empowerment- improving autonomy
- Patient / caregiver partnership in setting goals, action plans, presenting solutions
- Patient information – person to person – to acquire skills and confidence in self-care
- Health workers' time
- Changing physicians' attitudes: paternalistic to partnership

Community resources

- **Supporting patients needs**
- **Educational needs of young patients**
- **Patient support groups and assistance from without the reference centre**
- **Links between the Centre and community agencies – social assistance**
- **Health education and information to the public**

Additional standards

Links to primary/secondary services:

- Patients with poor access to the reference centre – distance, poverty
- Ethnic minorities/immigrant groups – scattered geographically
- Private/public sector relationship (does referral to the centre cancel the role of the private or primary care provider?)

Other duties of the thalassaemia service

- Epidemiological surveillance
- Collaboration/links with other national and international centres
- Close links with patient organisations

Conclusion: Expert centres

Sufficient activity and capacity to provide services, gain experience, and sustain quality:

What is the minimum throughput for each service?

Survival – treatment in specialised centres




Fig. 1. Kaplan–Meier overall survival curves of patients referred to specialized centers (IC) versus patients referred to nonspecialized centers (OC). Log-rank P -value < 0.0001 ; hazard ratio of OC versus IC adjusted for sex (Cox model): 18.1, 95% confidence interval = 4.7–69.0; $P < 0.001$.

12TH INTERNATIONAL CONFERENCE ON THALASSAEMIA AND THE HAEMOGLOBINOPATHIES
14TH INTERNATIONAL TIF CONFERENCE FOR THALASSAEMIA PATIENTS AND PARENTS
ANTALYA, TURKEY, 11-14 MAY, 2011

The Ideal Centre for Haemoglobinopathies

ANTONIO PIGA

THALASSEMIA & HEMOGLOBINOPATHIES CENTRE
DEPARTMENT OF CLINICAL AND BIOLOGICAL SCIENCES
SCHOOL OF MEDICINE AND HOSPITAL S. LUIGI GONZAGA,
UNIVERSITY OF TORINO
antonio.piga@unito.it

CENTER CHARACTERISTICS

- **Responsibility with a single doctor, remaining the same as long as possible**
- **Dedicated Centre**
- **Dedicated staff**
 - **Staff stability**
 - **Institutional setting**
 - **Adequate staff/patients ratio**



CENTRE CHARACTERISTICS

Adequate staff/patients ratio

- 1 nurse / 33 patients
- 1 doctor /50 patients
- 1 psychologist /100 patients
- 1 secretary /100 patients

from: WHO, Hereditary Diseases Program, 1994



CENTER CHARACTERISTICS

- Responsibility with a single doctor, remaining the same as long as possible
- Dedicated Centre
- Dedicated staff
 - Trained in Hbpaties
 - Career development
 - The quality as a target
 - Active care

“ACTIVE” CLINICAL CARE

- Set the appointment
- Plan tests
- Book tests
- Visit the patient
- Set case review
- Set patient-doctor conversation



ASSESSMENT OF IRON-RELATED COMPLICATIONS IN TM

1

COMPLICATIONS

- ◉ Heart Disease
- ◉ Liver Disease
- ◉ Diabetes
- ◉ Hypothyroidism
- ◉ Hypoparathyroidism
- ◉ Adrenal Insufficiency
- ◉ Hypogonadism, Infertility
- ◉ Growth Hormone Defic.
- ◉ Osteoporosis

2

TESTS (diagnosis)

- ◉ EKG, Echocardiogram, Holter
- ◉ ↑ALT, AST, ↑fibroscan
- ◉ OGTT
- ◉ ↑TSH, ↓fT3, ↓fT4
- ◉ ↓PTH, ↓Ca, ↓1,25(OH)₂VitD3
- ◉ ↓ACTH test
- ◉ ↓LH, ↓FSH, ↓sex hormones
- ◉ ↓GH, ↓IGF-I
- ◉ ↓DEXA

3

TESTS (risk)

- ◉ Cardiac Iron (MR)
- ◉ Liver Iron (MR, SQUID)
- ◉ Pancreas MR¹⁻⁴
- ◉ Liver Iron?
- ◉ Liver Iron?
- ◉ Liver Iron?⁵
- ◉ Pituitary Iron & Volume⁶
- ◉ Liver Iron?
- ◉ Liver Iron?

¹Au-2007; ²Noetzli-2009; ³Papakonstantinou-2009;
⁴Noetzli-2010; ⁵Scacchi-2010; ⁶Wood-2010;



ASSESSMENT OF IRON-RELATED COMPLICATIONS IN TM

Recommended Monitoring

LIVER & HEART	At diagnosis	0-3 y	3-10 y	10-18 y	Adulthood	More often, if:
ALT, AST	Yes	At transf.	At transf.	At transf.	At transf.	
Serum Ferritin	Yes	1-3 months	1-3 months	1-3 months	1-3 months	
Liver/spleen US	Yes	yearly	yearly	yearly	yearly	High risk
Liver fibrosis (Fibroscan)	Yes		yearly	yearly	yearly	High risk
Electrocardiogram	Yes		yearly	yearly	yearly	Severe iron overload, palpitations
Ecocardiogram	Yes			yearly	yearly	Severe iron overload, cardiac failure
Holter	No		Specific indication	Specific indication	Specific indication	Arrhythmia
Liver Iron (MRI, SQUID)	Yes	yearly	yearly	yearly	yearly	Severe iron overload, Treatment changes
Heart Iron (MRI)	No			yearly	yearly	Severe iron overload, Treatment changes



CONTINUITY OF CARE

- Rapid access to specific care
- Centre doctor available for consultation or sharing the responsibility of management in any condition like:
 - Emergency
 - In-patient
 - Infections
 - Heart failure
 - Splenectomy
 - Intensive chelation
 - Bone marrow transplant



Web THAL

Cartella clinica computerizzata per la thalassemia

User:

Password:





Archive selection
Archive: **3.Day Hospital**

Modify a record

Enter a new record

Patient (birth date)	
F	983)
F	1987)
F	5/1967)
F	09/1967)
F	/1980)
F	1975)
F	3)
F	4)
F	77)
F	966)
F	3)
F	12/1971)
F	ristabel (09/12/1977)
F	6)
F	/1957)
F	5/1972)
F	4)
F	/1964)
F	50)
F	978)

- Archives
- 1.Basic data
 - 2.Family tree
 - 3.Day Hospital**
 - 4.Investigations and Consultations
 - 5.Urinary Iron Excretion
 - 6.Intensive Chelation
 - 7. Annual Summary Chart
 - 8.Weekly Deferiprone Follow up
 - Blood Request Form
 - c1.Heart Assessment
 - c2.Holter E.K.G.
 - c3.Echocardiogram
 - c4.Ergospirometry



Print

Blood request form


Agenda

THALASSEMIA-ORIENTED COMPUTERIZED CLINICAL RECORD

Row data from
transfusion
chelation
tests
Complications
Therapies




Transfusional indexes
Iron balance
Appointments
Print-outs
Graphs
Multicentre studies





Archives structure





Archive selection
Archive: **3.Day Hospital**

Patient (birth date)	
F	983)
F	1987)
F	5/1967)
F	09/1967)
F	/1980)
F	1975)
F	)
F	4)
F	77)
F	966)
F	3)
F	12/1971)
F	ristabel (09/12/1977)
F	6)
F	/1957)
F	5/1972)
F	)
F	/1964)
F	50)
F	978)

- Archives
- 1.Basic data
 - 2.Family tree
 - 3.Day Hospital**
 - 4.Investigations and Consultations
 - 5.Urinary Iron Excretion
 - 6.Intensive Chelation
 - 7. Annual Summary Chart
 - 8.Weekly Deferiprone Follow up
 - Blood Request Form
 - c1.Heart Assessment
 - c2.Holter E.K.G.
 - c3.Echocardiogram
 - c4.Ergospirometry



**Annual
summary
chart**

Search

**Advanced
search**




**Export
data**

**Import lab
results**

TRANSFUSION


- High quality blood
- Comfortable setting
- Patient-oriented facility (day, night, holiday)





PROCEDURES

- Hemovigilance
- Splenectomy
- Fever
- Growth monitoring
- Chelation efficacy monitoring
- Chelation tolerability monitoring
- Intravenous Desferal
- Combination therapy
- Monitoring iron-related complications
- Family planning
- Pregnancy (follow up)
- BMT



CENTRE CHARACTERISTICS

- Responsibility with a single doctor, remaining the same as long as possible
- Dedicated Centre
- Dedicated staff
- Dedicated clinical record & procedures
- Availability of mental health professionals experienced in chronic diseases

CENTRE CHARACTERISTICS

- **Responsibility with a single doctor, remaining the same as long as possible**
- **Dedicated Centre**
- **Dedicated staff**
- **Dedicated clinical record & procedures**
- **Availability of mental health professionals experienced in chronic diseases**
- **Psychosocial support integrated in the global management**



GUIDELINES FOR PSYCHOSOCIAL SUPPORT

2 - Methods

a - Containment model:

- **Listening to**
- **Accepting**
- **Sharing**
- **Understanding**
- **Communicating**

GUIDELINES FOR PSYCHOSOCIAL SUPPORT

3 - Methods - Tools

- **Individual conversations**
- **Group meetings**
- **Summer camps**
- **Chelation clinic**
- **Staff meetings**
- **Interventions from mental health professionals and social worker**

CENTRE CHARACTERISTICS

- Responsibility with a single doctor, remaining the same as long as possible
- Dedicated Centre
- Dedicated staff
- Dedicated clinical record & procedures
- Availability of mental health professionals experienced in chronic diseases
- Psychosocial support integrated in the global management
- Multidisciplinary team



MULTIDISCIPLINARY TEAM

WHO

- 'Thalassemologist'
- Cardiologist
- Pneumologist
- Endocrinologist
 - Diabetologist
 - Reproduction gynecologist
 - Andrologist
- Hepatologist
- Radiologist
- Transplant specialist
- Psychiatrist/psychologist
- Social worker




HOW

- Doctor in charge: coordinating the team
- Doctor: sensitizing each specialist
- Nurse: organizing



CLINICAL PROBLEMS THAT REQUIRE SPECIFIC CARE

- Osteoporosis
- Hypoparathyroidism
- Infertility
- Biliary stones
- Kidney stones
- Leg ulcers
- Bone deaformities in adult patients



SPECIAL CARE AT SPECIAL MOMENTS

- **Presentation**
- **Start of transfusion**
- **Start of chelation**
- **Non compliance**
- **Onset of a serious complications**
- **Conventional treatment versus SCT**

THALASSEMIA AT PRESENTATION

- Set an accurate diagnosis
 - thal. genotype
 - RBC genotype
 - HLA genotype
- Support the parents
 - information
 - serial conversations
 - genetic counselling



STEM CELLS TRANSPLANTATION

1 For each patient:

- ➔ Information
- ➔ HLA typing of siblings (+relatives if parents have the same ethnic background)
- ➔ Set level of risk (grouping)

2 For patient with HLA identical relative:

- ➔ Detailed information (patient, donor, parents)

2a Informed consent=yes

- ➔ Make low risk SCT available

2b Informed consent=no

- ➔ Wait and update

3 For patient with no HLA identical relative:

- ➔ Consider BMT in special cases

4 For perspective couples at risk of thalassemia:


- ➔ Information
- ➔ Save cord blood

CENTRE CHARACTERISTICS


- **Responsibility with a single doctor, remaining the same as long as possible**
- **Dedicated Centre**
- **Dedicated staff**
- **Dedicated clinical record & procedures**
- **Availability of mental health professionals experienced in chronic diseases**
- **Psychosocial support integrated in the global management**
- **Multidisciplinary team**
- **Non invasive diagnostic techniques**



Haemoglobinopathies Centre



AGE OF PATIENTS



CLINICAL PROBLEMS

- Pediatrics
- Adult Medicine

TYPE OF UNIT

- Blood Bank
- Pediatric Unit
- Hematology Unit
- General Medicine Unit

**DEDICATED
HAEMOGLOBINOPATHIES
CENTRE**



Thalassemia
Research
Center



MAHIDOL UNIVERSITY
Wisdom of the Land





Thalassemia
Research
Center



MAHIDOL UNIVERSITY
Wisdom of the Land





**Thalassemia
Research
Center**



MAHIDOL UNIVERSITY
Wisdom of the Land





**Thalassemia
Research
Center**



MAHIDOL UNIVERSITY
Wisdom of the Land







**Thalassemia
Research
Center**



MAHIDOL UNIVERSITY
Wisdom of the Land





若夫妇双方均为同一类型的地中海贫血（以下简称地贫），其子女有1/4的机会为重型地贫患者。婚检可以提前发现，怀孕时要做产前筛查、产前诊断，才能有把握生下健康的孩子。



正常人和地贫基因携带者结婚，生育后代有两种结果：

- 1、后代是地贫基因携带者的几率为50%



- 2、后代正常的几率为50%



地贫基因携带者之间结婚，生育后代有三种结果：

- 1、后代正常的几率为25%



- 2、后代是地贫基因携带者的几率为50%



- 3、后代是重症地贫患儿的几率为25%
(红色显示就是需要重点干预的后代)



优生优育
父母职责

婚前医学
检查

产前筛查、
产前诊断

新生儿疾病
筛查

宝宝健康
家庭幸福

优生三环节



2nd International Conference on Thalassemia & Birth Defects

October 11, 2014, Nanning, China

第二届地中海贫血·出生缺陷预防国际研讨会 The 2nd International Conference on Thalassemia & Birth Defects

2014年10月11日 中国 南宁
October 11, 2014 Nanning, P. R. China

主办 Organizer

中华人民共和国国家卫生和计划生育委员会 National Health and Family Planning Commission of the People's Republic of China
国际地中海贫血联盟 Thalassemia International Federation

承办 Co-Organizer

中国妇幼保健研究会 China Association for Maternal and Child Health Studies
广西壮族自治区卫生和计划生育委员会 Health and Family Planning Commission of Guangxi Zhuang Autonomous Region
广西医科大学 Guangxi Medical University

迈克尔

李康

桑国卫

王国强

江帆

秦耕

李国坚

Nanning Declaration

第二届地中海贫血·出生缺陷预防 The 2nd International Conference on Thalassemia

2014年10月11日 中国 南宁
October 11, 2014 Nanning, P. R. China

主办 Organizer

中华人民共和国国家卫生和计划生育委员会 National Health and Family Planning Commission of the P.R. China
国际地中海贫血联盟 Thalassemia International Federation

承办 Co-Organizer

中国妇幼健康研究会 China Association for Maternal and Child Health Studies
广西壮族自治区卫生和计划生育委员会 Health and Family Planning Commission of Guangxi
广西医科大学 Guangxi Medical University





Thalassemia
Research
Center



MAHIDOL UNIVERSITY
Wisdom of the Land

第二届地中海贫 The 2nd International Co

Nanning Declaration



Prevention and Control of Thalassemia and Birth Defects ¶



NANNING DECLARATION ¶



[The 2nd International Conference on Thalassemia & Birth Defects, jointly organized by the National Health and Family Planning Commission (NHFPC) of the People's Republic of China and the Thalassemia International Federation (TIF) has been taking place on 11 October 2014 in Nanning, China. 100 government officials and experts from China, Cyprus, Indonesia and Thailand, together with conference

Nanning Declaration

October, 11, 2014, Nanning, China

1. Government-led and shared responsibilities
2. Raising awareness and encouraging social participation
3. Refocusing approaches to improve prevention
4. Extending research and health-promotion services
5. Collaborating actively and broadening exchange



WORLD HEALTH HOUSE, INDRAPRASTHA ESTATE, MAHATMA GANDHI MARG, NEW DELHI-110 002, INDIA WWW.SEARO.WHO.INT
TEL: 91-11-2337 0804, 2337 0809–11 FAX: 91-11-2337 0197, 2337 9395, 2337 9507

Thematic Group Meeting on Management & Prevention of Thalassemia 7 to 8 August 2014, New Delhi, India

The objectives of the meeting are as follows:

- To learn from the experiences of the countries
- To review draft regional guidelines on management and prevention of Thalassemia

Thematic Group Meeting on Management & Prevention of Thalassemia



The Lalit Hotel
Barakhamba Avenue, Connaught Place,
New Delhi, India

August 7-8, 2014